SG11201905259SA - Preferred pairing of antibody domains - Google Patents

Preferred pairing of antibody domains

Info

Publication number
SG11201905259SA
SG11201905259SA SG11201905259SA SG11201905259SA SG11201905259SA SG 11201905259S A SG11201905259S A SG 11201905259SA SG 11201905259S A SG11201905259S A SG 11201905259SA SG 11201905259S A SG11201905259S A SG 11201905259SA SG 11201905259S A SG11201905259S A SG 11201905259SA
Authority
SG
Singapore
Prior art keywords
international
antibody
domain
domains
pct
Prior art date
Application number
SG11201905259SA
Inventor
Florian Rüker
Maximilian Bönisch
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SG11201905259SA publication Critical patent/SG11201905259SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 09 August 2018 (09.08.2018) WIP0 I PCT ill 1111u°11101llioIIl °nolo DID mil HE Elmo mnio oimIE (10) International Publication Number WO 2018/141894 Al (51) International Patent Classification: CO7K 16/28 (2006.01) (21) International Application Number: PCT/EP2018/052624 (22) International Filing Date: 02 February 2018 (02.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17154388.7 02 February 2017 (02.02.2017) EP (71) Applicant: MERCK PATENT GMBH [DE/DE]; Frank- furter StraBe 250, 64293 Darmstadt (DE). (72) Inventors: RUKER, Florian; Montigasse 6, 1170 Vien- na (AT). BONISCH, Maximilian; Boerhaavegasse 3/2/10, 1030 Vienna (AT). (74) Agent: REDL, Gerda et al.; REDL Life Science Patent At- torneys, Donau-City-StraBe 11, 1220 Vienna (AT). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). — Published: with international search report (Art. 21(3)) 00 (54) Title: PREFERRED PAIRING OF ANTIBODY DOMAINS 1-1 0, - -- 13 (57) : An antigen-binding molecule (ABM) comprising a cognate LC/HC dimer of an antibody light chain (LC) composed of a VL and a CL antibody domain, associated to an antibody heavy chain (HC) comprising at least a VH and a CH1 antibody domain, O which association is through pairing the VL and VH domains and the CL and CH domains, wherein the amino acids at the position 18 N in the CL domain and at the position 26 in the CH1 domain are of opposite polarity, wherein numbering is according to the IMGT.
SG11201905259SA 2017-02-02 2018-02-02 Preferred pairing of antibody domains SG11201905259SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17154388 2017-02-02
PCT/EP2018/052624 WO2018141894A1 (en) 2017-02-02 2018-02-02 Preferred pairing of antibody domains

Publications (1)

Publication Number Publication Date
SG11201905259SA true SG11201905259SA (en) 2019-08-27

Family

ID=57965749

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201905259SA SG11201905259SA (en) 2017-02-02 2018-02-02 Preferred pairing of antibody domains

Country Status (13)

Country Link
US (1) US20190352429A1 (en)
EP (1) EP3577137A1 (en)
JP (1) JP7123063B2 (en)
KR (1) KR20190113870A (en)
CN (1) CN110382537B (en)
AU (1) AU2018214208A1 (en)
BR (1) BR112019013648A2 (en)
CA (1) CA3050988A1 (en)
IL (1) IL268401A (en)
MX (1) MX2019007984A (en)
SG (1) SG11201905259SA (en)
WO (1) WO2018141894A1 (en)
ZA (1) ZA201903796B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180069839A (en) 2015-10-08 2018-06-25 자임워크스 인코포레이티드 Antigen-binding polypeptide constructs including kappa and lambda light chains and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU777192B2 (en) * 1994-05-27 2004-10-07 Ariad Gene Therapeutics, Inc. Immunosuppressant target proteins
ATE514717T1 (en) * 2002-07-18 2011-07-15 Merus B V RECOMBINANT PRODUCTION OF ANTIBODIES MIXTURES
SI1713503T1 (en) * 2004-02-10 2013-12-31 The Regents Of The University Of Colorado, A Body Corporate Inhibition of factor b, the alternative complement pathway and methods related thereto
CA2646965C (en) 2006-03-24 2016-06-21 Jonathan H. Davis Engineered heterodimeric protein domains
CA2693863C (en) 2007-07-17 2017-10-03 Merck Patent Gmbh Engineered anti-alpha v- integrin hybrid antibodies
CN101348475B (en) * 2007-07-20 2011-03-30 重庆人本药物研究院 Novel method for synthesizing orlistat, intermediate compound and preparation thereof
AU2010252284A1 (en) 2009-05-27 2011-11-17 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
JP6167040B2 (en) * 2010-11-05 2017-07-19 ザイムワークス，インコーポレイテッド Design of stable heterodimeric antibodies with mutations in the Fc domain
DK2773671T3 (en) * 2011-11-04 2021-11-15 Zymeworks Inc DESIGN OF STABLE HETERODIMED ANTIBODY WITH MUTATIONS IN THE FC DOMAIN
JP6203838B2 (en) * 2012-06-27 2017-09-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Method for selecting and creating tailor-made highly selective and multispecific targeting entities comprising at least two different binding entities and uses thereof
UY35148A (en) * 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
WO2014150973A1 (en) * 2013-03-15 2014-09-25 Eli Lilly And Company Methods for producing fabs and bi-specific antibodies
JP6904902B2 (en) * 2014-12-05 2021-07-21 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Domain exchange antibody

Also Published As

Publication number Publication date
AU2018214208A1 (en) 2019-07-11
JP2020505929A (en) 2020-02-27
ZA201903796B (en) 2022-11-30
EP3577137A1 (en) 2019-12-11
KR20190113870A (en) 2019-10-08
US20190352429A1 (en) 2019-11-21
CN110382537A (en) 2019-10-25
CN110382537B (en) 2023-07-25
JP7123063B2 (en) 2022-08-22
RU2019119391A3 (en) 2021-05-25
MX2019007984A (en) 2019-10-15
BR112019013648A2 (en) 2020-01-21
WO2018141894A1 (en) 2018-08-09
CA3050988A1 (en) 2018-08-09
IL268401A (en) 2019-09-26
RU2019119391A (en) 2021-03-02

Similar Documents

Publication Publication Date Title
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201901390TA (en) Tetracycline compounds and methods of treatment
SG11201811640SA (en) Multispecific antigen binding proteins and methods of use thereof
SG11201908820VA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201906373VA (en) Chemical compounds as inhibitors of interleukin-1 activity
SG11201907451XA (en) Substituted imidazo-quinolines as nlrp3 modulators
SG11201804915RA (en) Methods for treating huntington's disease
SG11201810970WA (en) Anti-egfr antibody drug conjugates
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201408536WA (en) METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201907650RA (en) Personal therapy and exercise monitoring and oversight devices, systems, and related methods
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201407534PA (en) New diazaspirocycloalkane and azaspirocycloalkane
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201908786VA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201906947SA (en) Antibodies to alpha-synuclein and uses thereof
SG11201408056YA (en) Fire suppression systems, devices, and methods
SG11201807720TA (en) Methods and systems for determining antibiotic susceptibility
SG11201908678XA (en) Methods and compositions for reduction of immunogenicity
SG11201908091QA (en) Aqueous anti-pd-l1 antibody formulation
SG11201908456VA (en) Linker units and molecular constructs comprising same
SG11201903602RA (en) Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody
SG11201810429UA (en) Anti-cd19 antibody formulations